Creating a Global Research Database That Connects Genetic Information and Long-term Health Data to Improve Personalized Treatment for People With Serious Mental Illness
GlobalMinds
Developing an Internationally-diverse, Linked Genomic and Longitudinal Phenotypic Research Dataset to Accelerate Precision Psychiatry for Patients With Serious Mental Illness
2 other identifiers
observational
50,000
1 country
1
Brief Summary
This observational study aims to provide new insights into the nature and classification of severe mental illness and dementias that in time should help improve diagnostic practise, and enable the development of new and improved treatments. The investigators will achieve aims by gathering information and biological samples from over 50,000 research participants and then linking this information with participants' electronic health records, genetic and other potential markers of mental illnesses (called biomarkers, derived from biological samples). The investigators will use this resource to analyse how potential risk factors - genetic, other biological and non-biological (related to the participants' life circumstances) - influence participants' experiences, symptoms, and outcomes (both mental and physical health). The investigators will also use advanced analysis to assess whether there may be better ways of grouping together and understanding the experiences of those with severe mental illnesses and dementias. Given the value and importance of this resource for advancing mental health research, the investigators will also make the data available to other researchers to pursue these broad research aims.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2025
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 8, 2024
CompletedFirst Posted
Study publicly available on registry
October 15, 2024
CompletedStudy Start
First participant enrolled
May 16, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2035
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 1, 2035
October 3, 2025
September 1, 2025
9.6 years
October 8, 2024
September 30, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Diagnosis of participants with schizophrenia, bipolar disorder or schizoaffective disorder
The primary outcome measure of this study is the diagnosis of participants with bipolar disorder, schizophrenia or schizoaffective disorder in accordance with ICD-10 criteria
1 month from sample collection and baseline assessment.
Study Arms (3)
Cohort 1
40,000 participants with linked EHR and baseline assessments will provide a DNA sample only, via saliva or blood. This cohort will comprise even distribution across neuropsychiatric disorders including Schizophrenia, Major depressive disorder (MDD), and Bipolar diagnostic groups (approximately 13,300 patients in each group).
Cohort 2
9,000 participants with linked EHR and baseline assessments patients will provide DNA, RNA, peripheral blood mononuclear cells (PBMCs), plasma and serum via blood. This cohort will also comprise even distribution across neuropsychiatric disorders including Schizophrenia, Major depressive disorder (MDD), and Bipolar diagnostic groups (approximately 3000 patients in each group).
Cohort 3
1000 participants with Dementia who have linked EHR and assessments will provide DNA, RNA, peripheral blood mononuclear cells (PBMCs), plasma and serum via blood.
Interventions
This is non-interventional, cross-sectional observational study and thus there is no intervention.
Eligibility Criteria
Participants aged 18 and over with neuropsychiatric (MDD, BD or Schizophrenia) or Neurodegenerative disorder (dementia).
You may qualify if:
- \- All participants must have an electronic health record in a primary or secondary care service.
- Mental Health cohort(s) • Have received a diagnosis and/or treatment/referral for mental illness for MDD, BD, Schizophrenia.
- Having an available electronic health record
- Current age 18+ (no upper age limit)
- Can speak English Dementia cohort
- Participants aged 18+ (no upper age limit)
- Currently alive and are, or have been, old age psychiatry patients
- Received relevant diagnosis or referral:
- EITHER
- Clinical diagnosis of dementia, mild cognitive impairment (MCI) or subjective cognitive impairment (SCI) OR
- Memory clinic referral
- Must be willing and able to complete a validated cognitive assessment (MoCA or SLUMS).
- All dementia patients will undergo the extended biomarker analysis.
You may not qualify if:
- \- Mental Health cohort(s)
- Patients without capacity to provide consent. Dementia cohort
- Inability to understand spoken and/or written spoken English
- Individuals with intellectual disability.
- Patients with dementia in Creutzfeldt-Jakob disease (CJD), Huntington's, HIV dementia, alcohol-related dementia, intellectual disability, traumatic brain injury at any time.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Akrivia Healthlead
- Cardiff Universitycollaborator
Study Sites (1)
GlobalMinds central study team
Oxford, Oxford, OX1 3HJ, United Kingdom
Biospecimen
Extracted DNA samples, plasma, serum and derived PBMCs
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Prof. James Walters
Cardiff University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Target Duration
- 14 Days
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 8, 2024
First Posted
October 15, 2024
Study Start
May 16, 2025
Primary Completion (Estimated)
January 1, 2035
Study Completion (Estimated)
July 1, 2035
Last Updated
October 3, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will not share
Anonymised data will be shared with researchers at the discretion of the data access committee, but no individual identifiable patient data will be shared.